Sign In
Buy HCWB
$3.20
+0.0500 (+1.59%)
At Close: Jul 31, 2026
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday
02:48am, Wednesday, 25'th Mar 2026
HCW Biologics (NASDAQ: HCWB - Get Free Report) is expected to be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.84) per
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
07:50am, Tuesday, 17'th Mar 2026
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
08:00am, Monday, 02'nd Mar 2026
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
09:50pm, Tuesday, 17'th Feb 2026
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing inn
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
08:30am, Friday, 13'th Feb 2026
HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with H
Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX)
01:14am, Tuesday, 23'rd Dec 2025
HCW Biologics (NASDAQ: HCWB - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based o
Analyzing Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) & HCW Biologics (NASDAQ:HCWB)
02:08am, Wednesday, 10'th Dec 2025
HCW Biologics (NASDAQ: HCWB - Get Free Report) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ - Get Free Report) are both medical companies, but which is the better investment? We will compare the two c
HCW Biologics (NASDAQ:HCWB) Trading Down 7.1% – Here’s What Happened
02:26am, Tuesday, 02'nd Dec 2025
HCW Biologics Inc. (NASDAQ: HCWB - Get Free Report) traded down 7.1% during mid-day trading on Monday. The company traded as low as $1.96 and last traded at $1.97. 20,121 shares traded hands during tr
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
07:25am, Tuesday, 18'th Nov 2025
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions o
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
04:44pm, Friday, 14'th Nov 2025
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors Tetr
HCW Biologics to Participate in the 2025 Maxim Growth Summit
09:25am, Thursday, 16'th Oct 2025
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing inno
Watch the "What This Means" video here
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
09:15am, Thursday, 18'th Sep 2025
Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- H
